Agenus vs Mesoblast

AGEN and MESO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

agenAgenus$6.87+60.9% in 1 year

mesoMesoblast$13.27−15.5% in 1 year

How AGEN and MESO compare

Mesoblast grew revenue faster over the last twelve months (599% versus 25.4% for Agenus).

Mesoblast scores higher on the StockData Score (6 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

Metric	AGEN	MESO
Size and price
Market cap	$309M	–
Share price	$6.87	$13.27
Change, 1 year	60.9%	−15.5%
Change, 5 years	−90.2%	6.3%
Beta (5Y)	2.03	1.50
Employees	81	108
StockData Score
Total score	3	6 (better)
Valuation score	1 (better)	0
Growth score	2	3 (better)
Performance score	0	2 (better)
Health score	0	1 (better)
Dividend score	0	0
Valuation
P/S	2.3×	–
EV/EBITDA	4.5×	–
FCF yield	−33.6%	–
Growth
Revenue growth (TTM)	25.4%	599% (better)
Revenue growth, 5Y average	5.3%	74.5% (better)
Profitability
Gross margin	100% (better)	86.1%
Operating margin	38.9%	–
Net margin	–	−47.8%
FCF margin	−77.5%	−37.1% (better)
Financial health
Net debt / EBITDA	−1.05	–
Interest coverage	0.9×	–
Current ratio	0.73	2.43 (better)
Altman Z-score	−10.71	–
Piotroski F-score	–	5
Dividends and buybacks
Shareholder yield	0.00%	–
Ownership
Held by institutions	31.7%	0.30%
Held by insiders	6.6%	37.3%
Insider net buying, 12 months	–	$37.5M
Short interest, % of float	18.1%	–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.